RecruitingNot ApplicableNCT04564391

Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins

Molke Oder Casein - Leberfettreduktion Und Stoffwechselverbesserung Durch Schnelle vs. Langsame Proteine (Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins)


Sponsor

Charite University, Berlin, Germany

Enrollment

80 participants

Start Date

Sep 21, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

High-protein diets have been recently demonstrated to effectively reduce insulin resistance, derangements of the lipid profile and liver fat content in subjects with moderately and severely impaired glucose metabolism and non-alcoholic fatty liver disease (LeguAN, LEMBAS, DiNA-P, DiNA-D). The effects can be attributed to prolonged insulin secretion and improved second meal effect, higher energy expenditure by urea synthesis, suppression of glucagon or other mechanisms. Up to now, it is unclear, if proteins with slower or faster digestibility lead to differential results in these study designs. The proposed study will elucidate this question. The Investigators hypothesize, that slowly-digestible proteins induce a prolonged insulin plateau supporting the second-meal effect. The investigators also assume, that these dietary proteins lead to a markedly stronger short-term secretion of glucagon followed by desensitisation of this hormone release. Fast-digestible proteins, on the other hand, will presumably induce a smaller second-meal effect and do not inhibit a second rise of glucagon in a consecutive meal. The investigators intend to study the effects of a 3-weeks high-protein diet in 80 subjects with NAFLD and T2DM on liver fat content (MR spectroscopy) and glucose metabolism. The investigators expect different results for slow protein (casein) and fast protein (whey), thus comparing both protein species. The two major clinical visits before and after the intervention period will include MRI spectroscopy, fasting blood sampling for later analysis, full anthropometric assessment, a mixed meal tolerance test and a set of behavioral tests, investigating decision making processes. In order to characterize the postprandial profiles (e.g. insulin, glucagon, amino acids) of the varying protein sources, preliminary meal tests are performed in overweight subjects with and without T2DM.


Eligibility

Min Age: 18 YearsMax Age: 79 Years

Inclusion Criteria7

  • Subcohort 1 (n=46):
  • healthy glucose levels or T2DM
  • years
  • overweight/obesity
  • T2DM
  • with NAFLD
  • years

Exclusion Criteria16

  • type 1 diabetes, prediabetes
  • currently receiving treatment with insulin
  • lactose intolerance, or food intolerance/allergy to any of the study products
  • severe endocrine, gastrointestinal, metabolic, cardiovascular, pulmonary, inflammatory or psychiatric disorder
  • active or recent relevant cancer
  • intake of glucocorticoids or other medication that influences glucose metabolism
  • pregnancy, breastfeeding
  • Subcohort 2 (n=80):
  • type 1 diabetes, prediabetes
  • currently receiving treatment with insulin
  • lactose intolerance, or food intolerance/allergy to any of the study products
  • severe endocrine, gastrointestinal, metabolic, cardiovascular, pulmonary, inflammatory or psychiatric disorder
  • active or recent relevant cancer
  • intake of glucocorticoids or other medication that influences glucose metabolism
  • pregnancy, breastfeeding
  • claustrophobia

Interventions

DIETARY_SUPPLEMENTprotein supplement

protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients

DIETARY_SUPPLEMENTplacebo supplement

Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients


Locations(1)

Charité Campus Benjamin Franklin

Berlin, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04564391


Related Trials